Efficacy and Safety of Catheter Ablation of Atrial Fibrillation in Patients With Thyroid Hormone Stabilization
Launched by THE SECOND AFFILIATED HOSPITAL OF JIAXING UNIVERSITY · Jun 5, 2024
Trial Information
Current as of July 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
In patients recommended by guidelines for atrial catheter radiofrequency ablation of atrial fibrillation, catheter radiofrequency ablation was performed after exclusion of contraindications, and was observed and compared between patients with comorbid pre-existing thyroid hormone disorders and patients without comorbid atrial fibrillation after radiofrequency ablation:1: time to sexual rhythm maintenance: incidence of cardiac-related complications and incidence of noncardiac-related complications within 3 months and 1 year,2: walking distance on a six-minute walk test within 3 months,1 year...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Atrial Fibrillation Requiring Catheterized Radiofrequency Ablation （Class I Recommendation）
- Exclusion Criteria:
- • Atrial Fibrillation Requiring Catheterized Radiofrequency Ablation Class I Recommendation With Coexisting Contraindications
About The Second Affiliated Hospital Of Jiaxing University
The Second Affiliated Hospital of Jiaxing University is a prominent clinical research institution dedicated to advancing medical knowledge and improving patient care through innovative clinical trials. As part of a comprehensive academic health system, the hospital leverages its robust clinical expertise and state-of-the-art facilities to conduct rigorous research across various medical disciplines. Committed to ethical standards and patient safety, the hospital fosters collaboration among healthcare professionals, researchers, and academic partners to facilitate the development of new therapies and treatment protocols that enhance health outcomes in the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jiaxing, Zhejiang, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported